Asymmetric synthesis of propargylamines as amino acid surrogates in peptidomimetics

• Matthias Wünsch,
• David Schröder,
• Tanja Fröhr,
• Lisa Teichmann,
• Sebastian Hedwig,
• Nils Janson,
• Clara Belu,
• Jasmin Simon,
• Shari Heidemeyer,
• Philipp Holtkamp,
• Jens Rudlof,
• Lennard Klemme,
• Alessa Hinzmann,
• Beate Neumann,
• Hans-Georg Stammler and
• Norbert Sewald

Beilstein J. Org. Chem. 2017, 13, 2428–2441, doi:10.3762/bjoc.13.240

• proteases [7], cruzain 20 [8][9], caspases [10] and peptidyl aminopeptidases [11]. These protease inhibitors show potential for the treatment of Chagas disease [2][9], Huntington’s disease [10], malaria [11], autoimmune diseases [6] and the imaging of tumor associated macrophages [2]. Whereas the carboxylic

Synthesis of alpha-tetrasubstituted triazoles by copper-catalyzed silyl deprotection/azide cycloaddition

• Zachary L. Palchak,
• Paula T. Nguyen and
• Catharine H. Larsen

Beilstein J. Org. Chem. 2015, 11, 1425–1433, doi:10.3762/bjoc.11.154

• . The Ellman group demonstrates the power of their chiral sulfinylimine protocol to synthesize propargylamine-derived alpha-tetrasubstituted triazoles (tetrasubstituted carbon bearing amine highlighted in red, Figure 1). One such triazole is a cruzain inhibitor with activity against parasite Trypanosoma

• triazoles. A sampling of propargylamine-derived triazoles with therapeutic effects includes alpha-tetrasubstituted triazoles as cruzain and cathepsin inhibitors. A tetrasubstituted carbon bearing an amine (red) can provide 100-fold increase in activity compared to the trisubstituted carbon bearing an amine

Chemical–biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target

• Jonathan W. Choy,
• Clifford Bryant,
• Claudia M. Calvet,
• Patricia S. Doyle,
• Shamila S. Gunatilleke,
• Siegfried S. F. Leung,
• Kenny K. H. Ang,
• Steven Chen,
• Jiri Gut,
• Juan A. Oses-Prieto,
• Jonathan B. Johnston,
• Michelle R. Arkin,
• Alma L. Burlingame,
• Jack Taunton,
• Matthew P. Jacobson,
• James M. McKerrow,
• Larissa M. Podust and
• Adam R. Renslo

Beilstein J. Org. Chem. 2013, 9, 15–25, doi:10.3762/bjoc.9.3

• , 1700 4th Street, San Francisco, CA, 94158, USA Cellular Ultra-Structure Laboratory, Oswaldo Cruz Institute (IOC), FIOCRUZ, Rio de Janeiro, RJ, Brazil 21040-362 10.3762/bjoc.9.3 Abstract Inhibition of the Trypanosoma cruzi cysteine protease cruzain has been proposed as a therapeutic approach for the

• treatment of Chagas’ disease. Among the best-studied cruzain inhibitors to date is the vinylsulfone K777 (1), which has proven effective in animal models of Chagas’ disease. Recent structure–activity studies aimed at addressing potential liabilities of 1 have now produced analogues such as N-[(2S)-1-[[(E,3S

• of this new class of inhibitors. Keywords: activity-based probes; Chagas’ disease; cruzain; CYP51; 14-α-demethylase; hybrid drugs; Trypanosoma cruzi; Introduction The kinetoplastid protozoan Trypanosoma cruzi is the causative agent of Chagas’ disease, a leading cause of heart failure in endemic